Lenvaxen 10 mg (Lenvatinib) is an innovative oral medication designed to treat several types of advanced cancers, including thyroid cancer, renal cell carcinoma (RCC), and hepatocellular carcinoma (HCC). The active ingredient, Lenvatinib, is a multi-targeted tyrosine kinase inhibitor (TKI) that works by blocking the signals that promote the growth of cancer cells and the formation of blood vessels that supply…
Lenvaxen (Lenvatinib) is a powerful oral medication used to treat various types of cancer, including thyroid cancer, renal cell carcinoma (RCC), and hepatocellular carcinoma (HCC). The active ingredient in Lenvaxen is lapatinib, a tyrosine kinase inhibitor (TKI) that works by blocking multiple enzymes responsible for the growth and spread of cancer cells. This targeted approach helps slow down tumour growth,…
Lenvaxen 4mg (Lenvatinib) is a powerful, targeted cancer therapy specifically designed to treat advanced thyroid cancer, hepatocellular carcinoma (liver cancer), and renal cell carcinoma (kidney cancer). This innovative medication inhibits specific proteins that promote tumour growth and spread, slowing cancer progression. Lenvaxen 4mg has become a trusted choice for oncologists worldwide due to its efficacy in targeting multiple cancer types,…
Lorbrexen 100 mg (lorlatinib) is an innovative oral medication used to treat non-small cell lung cancer (NSCLC) in patients with a specific gene mutation known as ALK-positive . This cutting-edge therapy is designed to slow the progression of Cancer, offering hope for patients in the advanced stages of Treatment For Lung Cancer where other treatments may have failed. With Lorbrexen,…
Lorbrexen (Lorlatinib 100mg) is an innovative cancer therapy specifically designed to treat non-small cell lung cancer (NSCLC) that is positive for ALK (anaplastic lymphoma kinase) mutations. This targeted therapy is highly effective in managing advanced stages of ALK-positive NSCLC, especially in patients whose cancer has progressed despite prior treatment with other ALK inhibitors. Lorbrexen works by blocking the activity of…
Unlock a new avenue of hope in targeted cancer therapy with Mobocertinib 40 mg (Moboxen), a cutting-edge therapy specifically designed for patients with non-small cell lung cancer (NSCLC) harboring specific EGFR mutations. With a focus on precision medicine, Mobocertinib offers a targeted approach that aims to inhibit tumor growth while minimizing side effects, making it a valuable option for those…
Niranib 100mg (Niraparib) is an advanced oral medication used for the maintenance treatment of ovarian, fallopian tube, and primary peritoneal cancers. It's part of a group of cancer treatments known as PARP inhibitors, which target and destroy cancer cells by preventing them from repairing their DNA. Niranib offers new hope for patients who are in remission following successful treatment with…
Obetix 5 mg (Obeticholic Acid) is a breakthrough medication designed to treat primary biliary cholangitis (PBC), a chronic liver disease that causes inflammation and damage to the bile ducts. Obeticholic acid, the active ingredient in Obetix, works by activating the farnesoid X receptor (FXR), a key regulator in bile acid metabolism. This helps reduce liver inflammation and damage, slowing the…
Olanib 50mg & 150mg (Olaparib) is a leading-edge oral medication used to treat various cancers, specifically ovarian, breast, prostate, and pancreatic cancers. This powerful drug belongs to a class of treatments known as PARP Inhibitor For Prostate Cancer (Poly ADP-Ribose Polymerase inhibitors). It is designed to stop cancer cells from repairing themselves, slowing tumour growth and enhancing survival rates.
Osicent 80mg (Osimertinib) is a groundbreaking medication designed for the treatment of non-small cell lung cancer (NSCLC) in patients with specific epidermal growth factor receptor (EGFR) mutations, including the resistant T790M mutation. As a third-generation EGFR inhibitor, Osicent 80mg offers a targeted approach that is proven to be effective in treating advanced and metastatic stages of NSCLC, particularly when the…
Osimert 80mg, containing the active ingredient Osimertinib, is a potent medication for treating non-small cell lung cancer (NSCLC). As a third-generation tyrosine kinase inhibitor (TKI), Osimertinib specifically targets and inhibits the activity of epidermal growth factor receptor (EGFR) mutations, including T790M resistance mutations, which are commonly associated with the progression of New Cancer Treatment For Lung Cancer. This targeted approach…
Palbocent 125 mg (Palbociclib) is an innovative oral medication used to treat hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer. Palbociclib, the active ingredient in Palbocent, is a selective inhibitor of cyclin-dependent kinases (CDK) 4 and 6, enzymes that play a crucial role in the growth and division of cancer cells. By blocking…
Palboxen 125mg, containing the active ingredient Palbociclib, is a groundbreaking medication specifically designed for the treatment of hormone receptor-positive (HR+), HER2-negative advanced or metastatic breast cancer. As a cyclin-dependent kinase (CDK) 4/6 inhibitor, Palboxen 125mg is vital in slowing down the growth and spread of cancer cells, offering hope to patients whose cancer has progressed after previous treatments. When used…
Ponatinix 45 mg (Ponatinib) is a cutting-edge, targeted therapy used to treat patients with chronic myeloid leukaemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukaemia (Ph+ ALL), particularly those who have become resistant to previous treatments. Ponatinib, the active ingredient in Ponatinix, is a third-generation tyrosine kinase inhibitor (TKI) that is especially effective against the T315I mutation, which makes many forms…
Ponaxen (Ponatinib) is a powerful medication designed to treat certain types of blood cancers, including chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL), that have shown resistance to other treatments. Available in both 45mg and 15mg doses, Ponaxen offers patients a cutting-edge approach by targeting abnormal proteins driving cancer growth, helping to control and manage the disease.
Renib 40 mg is a highly effective oral medication used to treat meertastatic castration-resistant prostate cancer (mCRPC) and non-metastatic castration-resistant prostate cancer (nmCRPC). The active ingredient, Enzalutamide, is a powerful androgen receptor inhibitor that works by blocking male hormones like testosterone from stimulating the growth of prostate cancer cells. This targeted therapy helps slow the progression of prostate cancer, offering…
Rizonib 250 mg (Crizotinib) is an advanced oral medication used to treat non-small cell lung cancer (NSCLC) that is ALK-positive (anaplastic lymphoma kinase-positive) or ROS1-positive. Crizotinib, the active ingredient in Rizonib, is a targeted therapy that works by inhibiting the abnormal proteins responsible for driving the growth of cancer cells. This powerful treatment offers hope for patients with advanced or…
Selinex 20mg (Selinexor) is a groundbreaking oral medication designed to treat multiple myeloma, diffuse large B-cell lymphoma (DLBCL), and other aggressive cancers. Selinexor, the active ingredient in Selinex, belongs to a new class of drugs known as Selective Inhibitors of Nuclear Export (SINE). It works by targeting and inhibiting XPO1, a protein involved in the export of tumor-suppressing proteins from…
Sotoxen 120mg (Sotorasib) is a revolutionary medication designed to target and treat non-small cell lung cancer (NSCLC) with a specific genetic mutation. This targeted therapy is specifically formulated for patients whose tumors carry the KRAS G12C mutation, a previously untreatable form of lung cancer. Sotoxen works by inhibiting the KRAS protein, slowing down the growth of cancer cells, and providing…
Tagrix-80mg (Osimertinib) is a life-changing medication designed to target and treat non-small cell lung cancer (NSCLC) that has specific EGFR (epidermal growth factor receptor) mutations. As an advanced third-generation EGFR inhibitor, it offers hope to patients who have developed resistance to earlier treatments. Tagrix is especially effective against tumors that harbor the T790M mutation, providing a tailored approach to Treatment…
Tucaxen 150mg, with the active ingredient Tucatinib, is a cutting-edge oral medication used in Her2 positive breast cancer treatment. Designed to target and inhibit the growth of cancer cells that overexpress the HER2 protein, Tucaxen 150mg is a key player in modern cancer therapy. It is often prescribed in combination with other cancer treatments, such as trastuzumab and capecitabine, to…
Venex 100mg, powered by the active ingredient Venetoclax, is a revolutionary oral treatment for specific blood cancers, including chronic lymphocytic leukaemia (CLL) and Acute Myeloid Leukemia (AML). This advanced medication targets and inhibits the BCL-2 protein, which plays a crucial role in helping cancer cells survive. By blocking this protein, Venex 100mg promotes cancer cell death, offering a highly effective…
Ventoxen 100mg, containing Venetoclax, is a breakthrough oral medication used to treat specific blood cancer treatment, including chronic lymphocytic leukaemia (CLL) and acute myeloid leukaemia (AML). This targeted therapy is designed to inhibit the BCL-2 protein, which plays a key role in cancer cell survival. It helps restore the body's natural ability to trigger cell death in cancerous cells. Ventoxen…
Wedica 100 mg (Trelagliptin) is an innovative, once-weekly oral medication designed to help control blood sugar levels in adults with Type 2 Diabetes. The active ingredient, Trelagliptin, is a DPP-4 inhibitor (dipeptidyl peptidase-4) that increases the levels of incretin hormones, which help regulate glucose metabolism. This convenient once-weekly tablet helps reduce blood sugar spikes after meals, improves overall glycemic control,…
